292 related articles for article (PubMed ID: 32005283)
1. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
Han K; Kwon O; Park HJ; Jung SY; Yang C; Son CG
Trials; 2020 Jan; 21(1):128. PubMed ID: 32005283
[TBL] [Abstract][Full Text] [Related]
2. A pilot study exploring the efficacy and safety of herbal medicine on Korean obese women with metabolic syndrome risk factors: Double blinded, randomized, multicenter, placebo controlled study protocol clinical trial.
Kim HJ; Ko Y; Kim H; Cha YY; Jang BH; Song YK; Ko SG
Medicine (Baltimore); 2020 Jan; 99(5):e18955. PubMed ID: 32000419
[TBL] [Abstract][Full Text] [Related]
3. A pilot study to evaluate the effect of Taeumjowi-tang on obesity in Korean adults: study protocol for a randomised, double-blind, placebo-controlled, multicentre trial.
Park S; Park JS; Cheon C; Yang YJ; An C; Jang BH; Song YK; Go H; Lee JA; Shin Y; Ko SG
Trials; 2012 Apr; 13():33. PubMed ID: 22483238
[TBL] [Abstract][Full Text] [Related]
4. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Hwangryunhaedok-tang (Huang-lian-jie-du-tang, Oren-gedoku-to) for patients with hyperlipidemia: a study protocol for a randomized, double-blind, placebo-controlled, parallel, investigator-initiated clinical trial.
Lee B; Han K; Park HJ; Kim AR; Kwon OJ; Yang C; Cho CS
Trials; 2020 Aug; 21(1):750. PubMed ID: 32854756
[TBL] [Abstract][Full Text] [Related]
6. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity.
Park SH; Lee JE; Lee SM; Lee J; Seo CS; Hwang GS; Jung J
J Ethnopharmacol; 2020 Oct; 260():112999. PubMed ID: 32454173
[TBL] [Abstract][Full Text] [Related]
7. Euiiyin-tang in the treatment of obesity: study protocol for a randomised controlled trial.
Cheon C; Jang S; Park JS; Ko Y; Kim DS; Lee BH; Song HJ; Song YK; Jang BH; Shin YC; Ko SG
Trials; 2017 Jun; 18(1):289. PubMed ID: 28637494
[TBL] [Abstract][Full Text] [Related]
8. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial.
Xu J; Wang R; You S; Zhang L; Zheng P; Ji G; Liu B
Trials; 2020 Jun; 21(1):512. PubMed ID: 32522273
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Kessoku T; Imajo K; Kobayashi T; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Saito S; Nakajima A
Contemp Clin Trials; 2018 Jun; 69():40-47. PubMed ID: 29627620
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Onkyeong-tang in treating cold hypersensitivity in the feet of Korean women: protocol for a double-blind, randomized, placebo-controlled, parallel-group, multicenter clinical study.
Lee KY; Han IS; Go HY; Lee DN; Yu JS; Sun SH
Trials; 2020 May; 21(1):410. PubMed ID: 32423429
[TBL] [Abstract][Full Text] [Related]
11. Exploring the efficacy and safety of herbal medicine on Korean obese women with or without metabolic syndrome risk factors: A study protocol for a double-blind, randomized, multi-center, placebo-controlled clinical trial.
Ko Y; Kim HJ; Kim H; Choi JB; Kwon YD; Jung WS; Jang BH; Kim N; Song YK; Ko SG
Medicine (Baltimore); 2020 Jul; 99(28):e21153. PubMed ID: 32664149
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean patients with cold hypersensitivity in the hands: study protocol for a pilot, double-blind, randomized, placebo-controlled, parallel-group clinical trial.
Ko Y; Go HY; Cho YY; Shin JH; Kim TH; Choi DJ; Lee JM; Jang JB; Song YK; Ko SG; Sun SH; Jeon CY
Trials; 2017 Jun; 18(1):268. PubMed ID: 28595610
[TBL] [Abstract][Full Text] [Related]
13. Sipjeondaebo-tang in patients with breast cancer with fatigue: a protocol for a pilot, randomised, double-blind, placebo-controlled, cross-over trial.
Cheon C; Kang S; Ko Y; Kim M; Jang BH; Shin YC; Ko SG
BMJ Open; 2018 Jul; 8(7):e021242. PubMed ID: 29982213
[TBL] [Abstract][Full Text] [Related]
14. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
15. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of Sipjeondaebo-tang in Korean patients with cold hypersensitivity in the hands and feet: a protocol for a pilot, randomized, double-blind, placebo-controlled, parallel-group clinical trial.
Ko Y; Sun SH; Han IS; Go HY; Kim TH; Lee JM; Jang JB; Park KS; Song YK; Lee KY; Jeon CY; Ko SG
Trials; 2019 Apr; 20(1):217. PubMed ID: 30987667
[TBL] [Abstract][Full Text] [Related]
17. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.
Sun Y; Chen G; Chen S; Wang Y; Hu Y; Zhao Y
Trials; 2022 Jun; 23(1):455. PubMed ID: 35655225
[TBL] [Abstract][Full Text] [Related]
20. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
Lee JE; Lee SM; Jung J
Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
